Clinical Features and Outcomes of the Patients with B-Cell Chronic Lymphoproliferative Disease in the New Drug Era.
10.19746/j.cnki.issn.1009-2137.2023.03.016
- Author:
Cheng-Bo XU
1
;
Min HU
1
;
Jian-Zhen SHEN
2
;
Hua-Qin XU
3
;
Rui-Ji ZHENG
4
Author Information
1. Department of Hematology， The People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine， Fuzhou 350004， Fujian Province， China.
2. Department of Hematology， Union Hospital， Fujian Medical University， Fujian Institute of Hematology， Fuzhou 350001， Fujian Province， China.
3. Department of Hematology， Zhangzhou Affiliated Hospital of Fujian Medical University， Zhangzhou 363000， Fujian Province， China.
4. Department of Hematology， Zhangzhou Affiliated Hospital of Fujian Medical University， Zhangzhou 363000， Fujian Province， China,E-mail：zhengruiji@sina.com.
- Publication Type:Journal Article
- Keywords:
B cell chronic lymphoproliferative disorders;
BTK inhibitor;
clinical features;
prognosis
- MeSH:
Humans;
Adult;
Female;
Male;
Middle Aged;
Aged;
Aged, 80 and over;
Rituximab/therapeutic use*;
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy*;
Retrospective Studies;
Lymphoma, Mantle-Cell;
Prognosis;
Lymphoma, B-Cell, Marginal Zone;
Lactate Dehydrogenases
- From:
Journal of Experimental Hematology
2023;31(3):722-729
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical characteristics of the patients with B-cell chronic lymphoproliferative disease（B-CLPD） in the new drug era and the effect of new drug treatment on efficacy and survival.
METHODS:The clinical and laboratory data of 200 cases B-CLPD patients diagnosed between April 2015 and August 2021 were analyzed retrospectively. The clinical efficacy and survival of the patients under different treatments including Bruton tyrosine kinase（BTK） inhibitors， rituximab， and chemotherapy alone were analyzed. The prognostic factors affecting the survival of patients were analyzed by univarite analysis and multivariate analysis.
RESULTS:There were 119 male（59.5％） and 81 female（40.5%） in 200 cases B-CLPD patients， the sex ratio(male/female) was 1.5∶1 with median age of 61（30- 91） years old. The distribution of subtypes were as fallows: 51 cases (25.5%) of chronic lymphocytic leukemia/small lymphocytic lymphoma（CLL/SLL）， 64（32.0%） cases of follicular lymphoma（FL）， 40（20.0%） cases mantle cell lymphoma（MCL）， 30（15.0%） cases of marginal zone lymphoma（MZL）， 10（5%） cases of lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia（LPL/WM）， 5（2.5%） cases of B cell chronic lymphoproliferative disorders unclassified（B-CLPD-U） . The main clinical manifestation of 102 patients was lymph node enlargement, 32 cases were complicated with B symptoms. Among CLL/SLL patients， there were 12（23.5%） cases in Binet A and 39（76.5%） cases in Binet B/C. There were 29 patients（20.9%） in Ann Arbor or Lugano stage I-II and 110 cases（79.1%） in stage III-IV of other subtypes. The complete remission（CR） rate was 43.1%（25/58）， 40.2%（39/97）， 7.1%（1/14）， and overaIl response rate（ORR） was 87.9%（51/58）， 62.9%（61/97）， 28.6%（4/14） in the groups of BTK inhibitors， rituximab-based therapy， and chemotherapy alone. The 3-year OS rate and PFS rate in all patients was 79.2% and 72.4% respectively. The 3-year OS rate of patient with MZL, CLL/SLL, FL,WM was 94.7%, 87.7%, 86.8% and 83.3% respectively, while the 3-year OS rate of MCL was only 40.6%, which was significantly lower than other subtypes. The median OS of patients treated with BTK inhibitors and rituximab-based therapy was 20.5 and 18.5 months respectively， and the 3-year OS rate was 97.4% and 90.7%. However， the median PFS of patients receiving chemotherapy alone was 4 months， and the 1-year OS rate was 52.7%， which was statistically significant compared with the other two groups（P<0.05）. Univarite analysis showed that anemia， elevated lactate dehydrogenase， elevated β2-microglobulin， and splenomegaly were the poor prognostic factors for OS（P<0.05）， elevated lactate dehydrogenase was also poor prognostic factors for PFS（P<0.05）. Multifactor analysis showed that anemia and elevated lactate dehydrogenase were the independent poor prognostic factors for survival（P<0.05）.
CONCLUSION:The clinical features of B-CLPD was various， anemia and elevated lactate dehydrogenase are the prognostic factors for poor survival. BTK inhibitors and new immunotherapy can improve the survival and prognosis of patients in the new drug era.
